Aardvark Therapeutics Faces Securities Fraud Lawsuit

The lawsuit alleges that Aardvark Therapeutics misled shareholders regarding its business operations and the safety profile of its drug candidate, ARD-101. According to the complaint, the company’s registration statement and subsequent public disclosures failed to reveal that the drug was less safe than represented, leading to an overstatement of its clinical and commercial prospects. Investors claim these omissions caused financial damages when the reality of the situation surfaced.

Those who purchased common stock traceable to the February 2025 initial public offering or acquired securities during the specified class period may be eligible for compensation. While a class action has been initiated, no class has been certified, meaning investors are not currently represented by counsel unless they retain their own. Participation in potential future recoveries does not require an investor to serve as a lead plaintiff, though those interested in the role must file a motion with the Court by the October 13 cutoff.